Efficacy and Safety of [²²⁵Ac]Ac-PSMA-617 Augmented [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

• Egile Nagusiak: Florian Rosar (Egilea), Jonas Krause (Egilea), Mark Bartholomä (Egilea), Stephan Maus (Egilea), Tobias Stemler (Egilea), Ina Hierlmeier (Egilea), Johannes Linxweiler (Egilea), Samer Ezziddin (Egilea), Fadi Khreish (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2021-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The use of ²²⁵Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with ¹⁷⁷Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma (mCR...